These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 14553868)

  • 1. Implementation of an evidence-based guideline to reduce duration of intravenous antibiotic therapy and length of stay for patients hospitalized with community-acquired pneumonia: a randomized controlled trial.
    Fine MJ; Stone RA; Lave JR; Hough LJ; Obrosky DS; Mor MK; Kapoor WN
    Am J Med; 2003 Oct; 115(5):343-51. PubMed ID: 14553868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a 3-step critical pathway to reduce duration of intravenous antibiotic therapy and length of stay in community-acquired pneumonia: a randomized controlled trial.
    Carratalà J; Garcia-Vidal C; Ortega L; Fernández-Sabé N; Clemente M; Albero G; López M; Castellsagué X; Dorca J; Verdaguer R; Martínez-Montauti J; Manresa F; Gudiol F
    Arch Intern Med; 2012 Jun; 172(12):922-8. PubMed ID: 22732747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of an inpatient management and discharge strategy for patients with community-acquired pneumonia.
    Stone RA; Mor MK; Lave JR; Hough LJ; Fine MJ
    Am J Manag Care; 2005 Aug; 11(8):491-9. PubMed ID: 16095435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can an antimicrobial stewardship program reduce length of stay of immune-competent adult patients admitted to hospital with diagnosis of community-acquired pneumonia? Study protocol for pragmatic controlled non-randomized clinical study.
    DiDiodato G; McArthur L; Beyene J; Smieja M; Thabane L
    Trials; 2015 Aug; 16():355. PubMed ID: 26272324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluating the impact of an antimicrobial stewardship program on the length of stay of immune-competent adult patients admitted to a hospital ward with a diagnosis of community-acquired pneumonia: A quasi-experimental study.
    DiDiodato G; McArthur L; Beyene J; Smieja M; Thabane L
    Am J Infect Control; 2016 May; 44(5):e73-9. PubMed ID: 26899527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Community-acquired pneumonia team decreases length of stay in hospitalized, low-risk patients with pneumonia.
    Marcos PJ; Restrepo MI; Sanjuàn P; Ferreira-Gonzalez L; Verea-Hernando H
    Hosp Pract (1995); 2013 Aug; 41(3):7-14. PubMed ID: 23948616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study.
    Capelastegui A; España PP; Quintana JM; Gorordo I; Ortega M; Idoiaga I; Bilbao A
    Clin Infect Dis; 2004 Oct; 39(7):955-63. PubMed ID: 15472846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of processes and outcomes of pneumonia care between hospitalists and community-based primary care physicians.
    Rifkin WD; Conner D; Silver A; Eichorn A
    Mayo Clin Proc; 2002 Oct; 77(10):1053-8. PubMed ID: 12374249
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia: link between quality of care and resource utilization.
    Battleman DS; Callahan M; Thaler HT
    Arch Intern Med; 2002 Mar; 162(6):682-8. PubMed ID: 11911722
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Community-acquired pneumonia: influence of the duration of intravenous antibiotic therapy on hospital stay and the cost-benefit ratio].
    Fernández Alvarez R; Gullón Blanco JA; Rubinos Cuadrado G; Jiménez Sosa A; Hernández García C; Medina Gonzálvez A; González Martín I
    Arch Bronconeumol; 2001 Oct; 37(9):366-70. PubMed ID: 11674935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Guideline-concordant antibiotic use and survival among patients with community-acquired pneumonia admitted to the intensive care unit.
    Frei CR; Attridge RT; Mortensen EM; Restrepo MI; Yu Y; Oramasionwu CU; Ruiz JL; Burgess DS
    Clin Ther; 2010 Feb; 32(2):293-9. PubMed ID: 20206787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia.
    Ramirez JA; Vargas S; Ritter GW; Brier ME; Wright A; Smith S; Newman D; Burke J; Mushtaq M; Huang A
    Arch Intern Med; 1999 Nov; 159(20):2449-54. PubMed ID: 10665893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of health care-associated pneumonia empirically treated with guideline-concordant regimens versus community-acquired pneumonia guideline-concordant regimens for patients admitted to acute care wards from home.
    Chen JI; Slater LN; Kurdgelashvili G; Husain KO; Gentry CA
    Ann Pharmacother; 2013 Jan; 47(1):9-19. PubMed ID: 23324506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicentre stewardship initiative to decrease excessive duration of antibiotic therapy for the treatment of community-acquired pneumonia.
    Foolad F; Huang AM; Nguyen CT; Colyer L; Lim M; Grieger J; Li J; Revolinski S; Mack M; Gandhi T; Wainaina JN; Eschenauer G; Patel TS; Marshall VD; Nagel J
    J Antimicrob Chemother; 2018 May; 73(5):1402-1407. PubMed ID: 29462306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of guideline-concordant empiric antibiotic therapy in community-acquired pneumonia.
    Frei CR; Restrepo MI; Mortensen EM; Burgess DS
    Am J Med; 2006 Oct; 119(10):865-71. PubMed ID: 17000218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tailored interventions to improve antibiotic use for lower respiratory tract infections in hospitals: a cluster-randomized, controlled trial.
    Schouten JA; Hulscher ME; Trap-Liefers J; Akkermans RP; Kullberg BJ; Grol RP; van der Meer JW
    Clin Infect Dis; 2007 Apr; 44(7):931-41. PubMed ID: 17342644
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inpatient care of community-acquired pneumonia: the effect of antimicrobial guidelines on clinical outcomes and drug costs in Canadian teaching hospitals.
    Marras TK; Jamieson L; Chan CK
    Can Respir J; 2004 Mar; 11(2):131-7. PubMed ID: 15045044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Hospital Practice Patterns for Antibiotic Administration for Pneumonia on Hospital Lengths of Stay and Costs.
    Christensen EW; Spaulding AB; Pomputius WF; Grapentine SP
    J Pediatric Infect Dis Soc; 2019 May; 8(2):115-121. PubMed ID: 29438527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing door-to-antibiotic time in community-acquired pneumonia: Controlled before-and-after evaluation and cost-effectiveness analysis.
    Barlow G; Nathwani D; Williams F; Ogston S; Winter J; Jones M; Slane P; Myers E; Sullivan F; Stevens N; Duffey R; Lowden K; Davey P
    Thorax; 2007 Jan; 62(1):67-74. PubMed ID: 16928714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in length of hospital stay in patients with community-acquired pneumonia: are shorter stays associated with worse medical outcomes?
    McCormick D; Fine MJ; Coley CM; Marrie TJ; Lave JR; Obrosky DS; Kapoor WN; Singer DE
    Am J Med; 1999 Jul; 107(1):5-12. PubMed ID: 10403346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.